Akkermansia muciniphila improves chronic colitis‐induced enteric neuroinflammation in mice
Neurogastroenterology & Motility · 2024-03 · 36 (3)
DOI: 10.1111/nmo.14745 ↗At a glance
Journal article in Neurogastroenterology & Motility, published online on 2024-01-23. Written by Ozgur Yilmaz and 8 co-authors. Institution: Department of Physiology, Institute of Health Sciences, Acibadem Mehmet Ali Aydinlar University, Istanbul, Turkey. Major MEDLINE topics: Colitis, Inflammatory Bowel Diseases. Cited 16 times so far (Crossref); 41 references. The full text is freely available (open access, CC BY-NC-ND 4.0). Funded by: Türkiye Bilimsel ve Teknolojik Araştırma Kurumu.
Abstract (original language)
Background
Inflammatory bowel diseases (IBD) are chronic diseases that are not fully understood. Drugs in use can only be applied for a short time due to their side effects. Therefore, research is needed to develop new treatment approaches. In addition, it has been proven that IBD causes degeneration in the enteric nervous system (ENS). In recent years, it has been discussed that probiotics may have positive effects in the prevention and treatment of inflammatory enteric degeneration. Akkermansia muciniphila ( A. muciniphila ) is an anaerobic bacterium found in the mucin layer of the intestinal microbiota. It has been found that the population of A. muciniphila decreases in the case of different diseases. In light of this information, the curative effect of A. muciniphila application on colitis‐induced inflammation and enteric degeneration was investigated.
Methods
In this study, 5 weeks of A. muciniphila treatment in Trinitro‐benzene‐sulfonic acid (TNBS)–induced chronic colitis model was investigated. Colon samples were examined at microscopic, biochemical, and molecular levels. Fecal samples were collected before, during, and after treatment to evaluate the population changes in the microbiota. Specific proteins secreted from the ENS were evaluated, and enteric degeneration was examined.
Results
As a result of the research, the ameliorative effects of A. muciniphila were shown in the TNBS colitis model‐induced inflammation and ENS damage.
Discussion
In light of these results, A. muciniphila can potentially be evaluated as a microbiome‐based treatment for IBD with further clinical and experimental studies.
Subjects
MeSH terms (MEDLINE)
Author keywords
Substances
Authors and institutions
- Department of Physiology, Institute of Health Sciences, Acibadem Mehmet Ali Aydinlar University, Istanbul, Turkey.
- Department of Microbiology, School of Medicine, Acibadem Mehmet Ali Aydinlar University, Istanbul, Turkey.
- Department of Histology and Embryology, School of Medicine, Acibadem Mehmet Ali Aydinlar University, Istanbul, Turkey.
- Research Unit of Comparative Microbiome Analysis, Helmholtz Zentrum Muenchen, Munich, Germany.
- Department of Surgery, School of Medicine Klinikum rechts der Isar, Technical University of Munich, Munich, Germany.
- Research and Transfer Working Group Enteric Nervous System (AGENS), University of Applied Sciences Kaiserslautern, Zweibrücken, Germany.
ORCID profiles: Ekin Demir
Funding
- Türkiye Bilimsel ve Teknolojik Araştırma Kurumu
Cite
APA
Yilmaz, O., Okullu, S. O., Catakci, M., Elmas, M. A., Pinheiro, Y., Arbak, S., Demir, E., Schaefer, K. H., & Kolgazi, M. (2024). Akkermansia muciniphila improves chronic colitis‐induced enteric neuroinflammation in mice. Neurogastroenterology & Motility, 36(3). https://doi.org/10.1111/nmo.14745
Vancouver
Yilmaz O, Okullu SO, Catakci M, Elmas MA, Pinheiro Y, Arbak S, et al. Akkermansia muciniphila improves chronic colitis‐induced enteric neuroinflammation in mice. Neurogastroenterology & Motility. 2024;36(3). doi:10.1111/nmo.14745
BibTeX
@article{Yilmaz2024,
author = {Yilmaz, Ozgur and Okullu, Sinem Oktem and Catakci, Merve and Elmas, Merve Acikel and Pinheiro, Yuri and Arbak, Serap and Demir, Ekin and Schaefer, Karl Herbert and Kolgazi, Meltem},
title = {Akkermansia muciniphila improves chronic colitis‐induced enteric neuroinflammation in mice},
journal = {Neurogastroenterology & Motility},
year = {2024},
volume = {36},
number = {3},
doi = {10.1111/nmo.14745}
}
EUVIMED